View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 21, 2011

Imprime PGG combination therapy found effective against cancer

Biothera's Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.

Biothera’s Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.

Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.

The open label multicentre randomised trial enrolled 90 patients to evaluate the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.

The aim of the study is to assess the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by the RECIST trial.

In pre-clinical cancer models, Imprime PGG has been found to reduce tumour growth and enhance long-term survival by killing neutrophils.

Imprime PGG is being investigated in a Phase III trial in KRAS wild-type colorectal cancer and several Phase II clinical trials in non small cell lung cancer and chronic lymphocytic leukaemia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena